Barclays
YMAB

Barclays’s Y-mAbs Therapeutics YMAB Stock Holding History

Barclays’s Portfolio YMAB Stock Details YMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-72,842
Closed -$329K – 5764
2025
Q2 		$329K Buy
72,842
+26,084
+56% +$117K ﹤0.01% 3999
2025
Q1 		$207K Sell
46,758
-29,104
-38% -$169K ﹤0.01% 4013
2024
Q4 		$594K Buy
75,862
+6,640
+10% +$80.9K ﹤0.01% 3720
2024
Q3 		$910K Buy
69,222
+56,244
+433% +$713K ﹤0.01% 3416
2024
Q2 		$157K Sell
12,978
-12,760
-50% -$172K ﹤0.01% 3701
2024
Q1 		$419K Sell
25,738
-24,699
-49% -$333K ﹤0.01% 3699
2023
Q4 		$344K Buy
50,437
+44,135
+700% +$255K ﹤0.01% 4121
2023
Q3 		$34.3K Sell
6,302
-1,015
-14% -$5.91K ﹤0.01% 4017
2023
Q2 		$49.7K Sell
7,317
-40,092
-85% -$300K ﹤0.01% 3832
2023
Q1 		$238K Buy
47,409
+37,550
+381% +$153K ﹤0.01% 3688
2022
Q4 		$48.1K Sell
9,859
-54,586
-85% -$397K ﹤0.01% 4566
2022
Q3 		$929K Buy
64,445
+61,634
+2,193% +$1.02M ﹤0.01% 2300
2022
Q2 		$43K Sell
2,811
-2,984
-51% -$34.8K ﹤0.01% 4091
2022
Q1 		$68K Sell
5,795
-54,183
-90% -$556K ﹤0.01% 3966
2021
Q4 		$972K Buy
59,978
+42,509
+243% +$909K ﹤0.01% 2855
2021
Q3 		$498K Buy
17,469
+10,615
+155% +$335K ﹤0.01% 3200
2021
Q2 		$232K Sell
6,854
-27,147
-80% -$871K ﹤0.01% 3481
2021
Q1 		$1.03M Buy
34,001
+21,857
+180% +$896K ﹤0.01% 2756
2020
Q4 		$602K Sell
12,144
-36,411
-75% -$1.68M ﹤0.01% 3129
2020
Q3 		$1.86M Sell
48,555
-3,449
-7% -$137K ﹤0.01% 2172
2020
Q2 		$2.25M Buy
52,004
+41,223
+382% +$1.56M ﹤0.01% 2015
2020
Q1 		$281K Sell
10,781
-17,281
-62% -$502K ﹤0.01% 4041
2019
Q4 		$878K Buy
28,062
+15,361
+121% +$454K ﹤0.01% 3791
2019
Q3 		$331K Sell
12,701
-418
-3% -$10.7K ﹤0.01% 4587
2019
Q2 		$300K Sell
13,119
-3,133
-19% -$72K ﹤0.01% 4761
2019
Q1 		$426K Buy
16,252
+5,913
+57% +$130K ﹤0.01% 4258
2018
Q4 		$210K Buy
+10,339
New +$237K ﹤0.01% 4542

Other funds holding YMAB

BIG
Brooklyn Investment Group Brooklyn, New York $3.2B AUM 26.32% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Barclays's YMAB Position: Q3 2025 in Review

Barclays sold out of Y-mAbs Therapeutics (YMAB) in Q3 2025, closing a stake of 72,842 shares — an estimated $329K sold.

Barclays first reported a position in YMAB in Q4 2018 and held it in 27 quarters. The position peaked at $2.25M in Q2 2020. 2 funds tracked by Wall St. Rank hold YMAB as of Q3 2025.

  • Barclays reported no remaining Y-mAbs Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Barclays sold 72,842 Y-mAbs Therapeutics shares in Q3 2025, an estimated $329K.
  • Barclays first reported a position in Y-mAbs Therapeutics in Q4 2018 and held it in 27 quarters.
  • Barclays's Y-mAbs Therapeutics position peaked at $2.25M in Q2 2020.
  • 2 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q3 2025.

Based on Barclays's 13F filing for Q3 2025, filed 12 Nov 2025.